A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)

Scientific reports, Volume 9, Issue 1, 2019, Pages 7390

Cited by: 0|Bibtex|Views3|Links
WOS

Abstract:

ENMD-2076, an aurora-A kinase inhibitor with anti-angiogenic properties, has shown activity in solid and hematologic malignancies. We investigated oral ENMD-2076 in an open-label, single-arm phase II study using 275 mg daily on a 28-day cycle in patients with advanced soft-tissue sarcomas (STS) receiving ≤1 line of prior therapy. Primary ...More

Code:

Data:

Your rating :
0

 

Tags
Comments